Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fibrosis Process Activation in Patients with Acute Cardiac Rejection: A Novel Noninvasive Diagnostic Approach.

Biomedicines·2026
Same author

Drug-coated balloons vs drug-eluting stents for the treatment of large native coronary artery disease. Meta-analysis of randomized controlled trials.

REC, interventional cardiology·2026
Same author

A laboratory-driven clinical decision support system algorithm for personalized and automated cardiovascular risk stratification in primary care patients.

Clinica chimica acta; international journal of clinical chemistry·2026
Same author

Renal function trajectories in 'De Novo' heart failure with reduced ejection fraction: impact on outcomes.

Open heart·2026
Same author

Automatic Detection of Vegetations With Transesophageal Echocardiography in Infective Endocarditis Using Artificial Intelligence.

Journal of imaging informatics in medicine·2025
Same author

Insights into the optimal blanking period after pulmonary vein isolation with radiofrequency or pulsed-field ablation.

Revista espanola de cardiologia (English ed.)·2025

Related Experiment Video

Updated: Jul 18, 2026

Isolation of Atrial Myocytes from Adult Mice
08:34

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

[Natriuretic peptides in heart failure].

Luis Almenar Bonet1, Luis Martínez-Dolz

  • 1Unidad de Insuficiencia Cardiaca y Trasplante, Servicio de Cardiología, Hospital Universitario La Fe, Valencia, Spain. lu.almenarb5@comv.es

Revista Espanola De Cardiologia
|December 6, 2006
PubMed
Summary

Heart-secreted natriuretic peptides, like BNP and NT-proBNP, aid in diagnosing and managing heart failure. Their levels offer valuable insights for patient care and treatment monitoring.

Area of Science:

  • Cardiology and Endocrinology: Focuses on cardiac hormones and their physiological roles.

Context:

  • The heart secretes hormones, particularly natriuretic peptides, in response to cardiac conditions.
  • Natriuretic peptides (ANP, BNP) and their fragments (NT-proANP, NT-proBNP) have diuretic, natriuretic, and vasodilatory effects.

Purpose:

  • To explore the clinical utility of natriuretic peptides in diagnosing, prognosing, screening, and monitoring heart failure patients.
  • To highlight the growing importance of NT-proBNP due to its stability and longer half-life compared to BNP.

Summary:

  • Plasma levels of natriuretic peptides are valuable biomarkers for heart failure.
  • NT-proBNP is increasingly favored over BNP for clinical applications due to its favorable pharmacokinetic properties.
  • These hormones play crucial roles in managing various aspects of heart failure care.

More Related Videos

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment
08:49

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

Related Experiment Videos

Last Updated: Jul 18, 2026

Isolation of Atrial Myocytes from Adult Mice
08:34

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment
08:49

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

Impact:

  • Provides evidence for the significant role of natriuretic peptides in cardiovascular medicine.
  • Supports the integration of natriuretic peptide testing into routine clinical practice for heart failure management.
  • Suggests future research directions focusing on NT-proBNP for improved patient outcomes.